In addition, the percentage of cases with multiproteinopathy is high, but this fact, is in accordance with recent studies that confirm the less important impact of co-pathologies on PSP progression (39) rate and demonstrates that tau burden is the strongest correlate with clinical manifestations (40). The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.